Market Report -- In Play (MDCO)
December 1, 2009 8:02 AM ET
The Medicines Co comfirms it receives European approval for Angiox for use in heart attack patients undergoing emergency heart procedures Co confirms that it has received European approval for the use of Angiox as an anticoagulant in patients with heart attacks (so-called ST-segment elevation myocardial infarction undergoing emergency heart procedures called primary percutaneous coronary intervention. The Commission Decision extends the current EU licence for Angiox and is applicable to all Member States of the European Union/European Economic Area. A positive CHMP opinion to include this new patient population was announced by the Company on October 23rd. Launch of Angiox in the new indication is planned for January 2010.
Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S. Bond, and world FX market participants.
Read more In Play articles
Back to News Home
- MSN Money
- Search MSN Money
- Message Boards
- Site Status
For today's top Money video click here
E-mail this article
Print-friendly version
Discuss this article